SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc. (AMEX: TTP) today reported, in accordance with requirements of the American Stock Exchange, that it has granted to Dr. Marc Rubin, pursuant to his joining the Company as President and Chief Executive Officer, 10-year options to purchase 1,500,000 shares of common stock at an exercise price of $2.40 per share. The options vest monthly over a four-year period, subject to a requirement of at least 12 months of employment for the vesting of any options.
